RSV Vaccination Recommendations for Adults Aged 60–74 Years

Recommendation Framework

• The Advisory Committee on Immunization Practices (ACIP) updated its RSV guidance in June 2024, shifting from shared clinical decision‑making to a clear age‑ and risk‑stratified approach: adults ≥ 75 years receive a universal single dose, whereas adults 60–74 years are vaccinated only if they possess at least one qualifying risk factor【1】【2】.

Qualifying Risk Factors for Adults 60–74 Years

Cardiovascular Conditions

• Chronic heart failure, coronary artery disease, or congenital heart disease (excluding isolated hypertension) qualify an adult 60–74 years for RSV vaccination【3】.

Respiratory Conditions

• Chronic obstructive pulmonary disease, asthma, emphysema, interstitial lung disease, or cystic fibrosis are qualifying respiratory risk factors【3】.

Metabolic and Renal Conditions

• End‑stage renal disease or dialysis dependence, diabetes with end‑organ complications, and diabetes requiring insulin or an SGLT2 inhibitor qualify for vaccination【3】.

Neurologic Conditions

• Disorders causing impaired airway clearance or respiratory‑muscle weakness (e.g., post‑stroke dysphagia, amyotrophic lateral sclerosis, muscular dystrophy) are qualifying risk factors; a history of stroke without ongoing airway impairment does not qualify【3】.

Other Chronic Conditions

• Chronic liver disease (e.g., cirrhosis), chronic hematologic disorders such as sickle‑cell disease or thalassemia, and severe obesity (BMI ≥ 40 kg/m²) qualify for vaccination【3】.

Immunocompromise and Living Situation

• Moderate or severe immunocompromise (as defined in COVID‑19 vaccination guidance), residence in a nursing home, and frailty (≥ 3 criteria of the Fried phenotype) are qualifying factors【1】【3】.

Implementation Considerations

Documentation Requirements

• Patient self‑attestation of a qualifying risk factor is sufficient; vaccinators should not deny vaccination due to lack of formal medical documentation【1】【3】.

Provider Flexibility

• Clinicians may offer RSV vaccine to patients they deem at increased risk even if the patient does not fall within an explicitly listed category, especially in remote or rural settings where transport is limited【1】【3】.

Common Pitfall to Avoid

• Isolated hypertension alone does not meet the qualification criteria for adults 60–74 years; the cardiovascular condition must include heart failure, coronary artery disease, or congenital heart disease【3】.

Rationale for the Risk‑Based Approach (Ages 60–74)

• Post‑licensure safety surveillance identified a potential increased risk of Guillain‑Barré syndrome (GBS) following protein‑subunit RSV vaccines (Arexvy, Abrysvo), prompting ACIP to limit universal use in this age group【4】【3】.
• Modeling demonstrated that, in high‑risk populations, the number of preventable RSV‑related hospitalizations, ICU admissions, and deaths exceeds the estimated vaccine‑attributable GBS cases, supporting targeted vaccination【4】.

Vaccine Details

Available Vaccines

• Three FDA‑approved RSV vaccines are acceptable for eligible adults 60–74 years: Arexvy (GSK, protein subunit), Abrysvo (Pfizer, protein subunit), and mResvia (Moderna, mRNA)【1】.

Dosing Schedule

• A single lifetime dose is recommended; individuals who have already received an RSV vaccine should not receive an additional dose【1】【5】.
• One dose provides protection for at least two consecutive RSV seasons【1】.

Optimal Timing

• Vaccination is preferably administered in late summer or early fall (August–October in the continental United States) before the RSV season, though it may be given at any time of year【1】.

Coadministration

• RSV vaccine may be co‑administered with the seasonal influenza vaccine at separate injection sites【1】.

RSV Vaccination Qualification for Adults 50-74

Age-Specific Qualification Framework

• The Centers for Disease Control and Prevention (CDC) recommends RSV vaccination for adults aged 50-74 years with chronic medical conditions, moderate/severe immunocompromise, nursing home residence, severe obesity, or other conditions that increase risk for severe respiratory viral disease, with patient attestation being sufficient evidence without requiring medical documentation 6, 7, 8
• Adults aged 60-74 years qualify for RSV vaccination if they have cardiovascular conditions such as chronic heart failure, coronary artery disease, or congenital heart disease (excluding isolated hypertension) 8
• The American College of Physicians (ACP) and CDC suggest that adults aged 60-74 years with pulmonary conditions like chronic obstructive pulmonary disease (COPD), asthma, emphysema, interstitial lung disease, or cystic fibrosis are eligible for RSV vaccination 7, 8
• Adults with renal disease, including end-stage renal disease or dependence on hemodialysis, are also eligible for RSV vaccination 8
• Complicated diabetes mellitus, including diabetes with chronic kidney disease, neuropathy, retinopathy, or other end-organ damage, is a qualifying condition for RSV vaccination 7, 8
• Neurologic/neuromuscular conditions such as impaired airway clearance, respiratory muscle weakness, poststroke dysphagia, amyotrophic lateral sclerosis, or muscular dystrophy qualify adults for RSV vaccination 7, 8
• Other chronic conditions like chronic liver disease, chronic hematologic conditions, or severe obesity (BMI ≥40 kg/m²) also qualify adults for RSV vaccination 7, 8
• Moderate or severe immunocompromise, including solid organ transplant recipients, hematopoietic stem cell transplant recipients, patients with malignancies, or those on immunosuppressive medications, is a qualifying condition for RSV vaccination 7, 8

Critical Implementation Points

• Patient attestation alone is sufficient evidence of a risk factor, and vaccinators should not deny vaccination due to lack of medical documentation 7, 8
• Qualified vaccinators may determine eligibility based on clinical assessment 6
• The CDC advises against denying RSV vaccination to adults with isolated hypertension or a history of stroke without ongoing impaired airway clearance 7, 8
• The Advisory Committee on Immunization Practices (ACIP) recommends maintaining flexibility in offering RSV vaccine to patients assessed to be at increased risk, even if they don't fall into an explicitly named category 7, 8
• All three FDA-approved RSV vaccines (Arexvy, Abrysvo, and mResvia) are acceptable for adults aged 60-74 years with risk factors, while only Arexvy is approved for adults aged 50-59 years with risk factors 6, 9